Summary
Proteins control cell function and measurement of their concentration is crucial for understanding their roles in health and disease. However, current methods for their detection in tissue sections are not quantitative. Radioimmunoluminography (RILG) is a system for direct measurement of quantity and distribution of protein in histological sections. Histological carcinomas were reacted with antigen-saturating concentrations of 125I-antibody to carcinoembryonic antigen (CEA). Antibody distribution and concentration was mapped by phosphor imaging. Radioactivity in each pixel of the digital image was proportional to antigen concentration, calculated from a standard line generated from a nitrocellulose CEA dot-blot assay. RILG gave a linear correlation with standards of known CEA concentration (r = 0.999). Six tumour xenografts with differing CEA concentrations by radioimmunoassay (RIA) were studied by RILG and immunohistochemistry (IHC). RILG gave a linear correlation with CEA by RIA (r = 0.994) but IHC failed to do so (r = 0.42). CEA levels measured by RILG, in cryostat (n = 15) and paraffin (n = 19) sections from colorectal cancer patients showed a range of CEA concentration (38.9–594 ng g−1 and 22.5–212.5 ng g−1 respectively). Tumour CEA concentration by RILG was significantly correlated with dose of antibody (% injected radioactivity kg−1) localized in tumour (P = 0.04 and P < 0.02 respectively), in patients receiving radioimmunoguided surgery. Clinical relevance of RILG is illustrated by identifying patients with high tumour CEA, most likely to benefit from antibody targeted therapy. Knowledge of the pathophysiology of many diseases may be enhanced by quantitative estimation of antigen concentration related to tissue morphology.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bagshawe, KD, Sharma, SK, Springer, CJ & Antoniw, P (1995). Antibody directed enzyme prodrug therapy: a pilot scale clinical trial. Tumour Targeting 1: 17–29.
Blair, SB, Theodorou, NA, Begent, RHJ, Dawson, PM, Salmon, M, Riggs, S, Kelly, AMB, Boxer, GM, Southall, PJ & Gregory, PA (1990). Comparison of anti-fetal colonic microvillus and anti-CEA antibodies in peroperative radioimmunolocalisation of colorectal cancer. Br J Cancer 61: 891–894.
Boxer, GM, Begent, RHJ, Kelly, AMB, Southall, PJ, Blair, SB, Theodorou, NA, Dawson, PM & Lederman, JA (1992). Factors influencing variability of localisation of antibodies to CEA in patients with colorectal carcinoma – implications for radioimmunotherapy. Br J Cancer 65: 825–831.
Chung, J-K, Jang, J-J, Lee, D-S, Lee, M-C & Koh, C-S (1994). Tumour concentration and distribution of carcinoembryonic antigen measured by in vitro quantitative autoradiography. J Nucl Med 34: 1499–1505.
Fraker, PJ & Speck, JC (1978). Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 80: 849–857.
Harwood, PJ, Britton, DW, Southall, PJ, Boxer, GM, Rawlins, G & Rogers, GT (1986). Mapping epitopes on carcinoembryonic antigen. Br J Cancer 54: 75–82.
Hitchens, RN, Begent, RHJ, Green, AJ, Searle, F, Van Heyningen, V & Bagshawe, KD (1989). Clinical value of imaging using antibody to alphafetoprotein in germ cell tumours. Nuklear Medizin 28: 29–33.
Jain, RJ (1989). Delivery of novel therapeutic agents in tumours: physiological barriers and stratagies. J Natl Cancer Inst 81: 570–576.
Lane, DM, Eagle, KF, Begent, RHJ, Hope-Stone, LD, Green, AJ, Casey, JL, Keep, PA, Kelly, AMB, Lederman, JA, Glaser, MG & Begent, RHJ (1994). Radioimmunotherapy of metastatic colorectal tumours with I-131 labelled antibody to CEA: phase I/II study with comparative biodistribution of intact and F(ab′)2 antibodies. Br J Cancer 70: 521–525.
Marshall, D, Pedley, RB, Melton, RG, Boden, JA, Boden, R & Begent, RHJ (1995). Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab′)2 fragments of an anti-tumour antibody. Br J Cancer 71: 18–24.
Okuyama, M, Hatori, Y & Shigematsu, A (1994). Autoradioluminography, a novel quantitative method of TLC-autoradiography. Biol Pharm Bull 17: 559–563.
Pedley, RB, Boden, JA, Boden, R, Boxer, GM, Flynn, AA, Keep, PA & Begent, RHJ (1996). Ablation of colorectal xenografts with combined radioimmunotherapy and tumour blood flow-modifying agents. Cancer Res 56: 3293–3300.
Poznansky, MR & Juliano, RL (1984). Biological approaches to the controlled delivery of drugs: a critical review. Pharmacol Rev 36: 277–336.
Shockley, TR, Lin, K, Nagy, A, Tompkins, RG, Dvorak, HF & Yarmush, ML (1991). Penetration of tumour tissue by antibodies and other immunoproteins. Ann NY Acad Sci 618: 367–381.
Southall, PJ, Boxer, GM, Bagshawe, KD, Hole, N, Bromley, M & Stern, P (1990). Immunohistologic distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer 61: 89–95.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Boxer, G., Stuart-Smith, S., Flynn, A. et al. Radioimmunoluminography: a tool for relating tissue antigen concentration to clinical outcome. Br J Cancer 80, 922–926 (1999). https://doi.org/10.1038/sj.bjc.6690443
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690443